Answers are grounded in this paper and cite their sources.
Given that traditional tumor therapy is associated with recurrence risk and immunotherapy is limited by the tumor immune microenvironment, alternative adjuvant approaches are urgently needed. In this context, active peptide-functional foods have emerged as promising auxiliary resources, yet their synergistic anti-tumor mechanisms are still not well understood, necessitating further research. In this paper, the dual functions of active peptides in direct tumor suppression and bidirectional regulation of immunity were analyzed. The synergistic principle of inducing immunogenic cell death and activating systemic anti-tumor immunity was elucidated by Gramicidin S and its light-controlled derivatives. Four types of synergistic methods, including molecular modification, light-controlled administration, combination therapy, and nanocarriers, were summarized. It was pointed out that these peptides had problems such as lack of preparation standards and only stopping in vitro experiments. This study clarified the mechanism of active peptide combined with immunotherapy, and provided theoretical support for the development of anti-tumor active peptide food. The existing in vivo pharmacological data are insufficient, and the Immunogenic cell death (ICD) regulatory pathway can be further analyzed in the future, so as to improve the in vivo efficacy and standardized production research and promote its clinical transformation.
No takes yet. Share an insight, caveat, or question.
Weijia Liu (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: